Skip to main content

Share story

Capital

InScope nabs $14.5M to solve the pain of financial reporting

InScope nabs $14.5M to solve the pain of financial reporting Image: Primary
InScope raised 14.5 million dollars in Series A funding led by Norwest. Storm Ventures and existing backers Better Tomorrow Ventures and Lightspeed Venture Partners joined the round. Co-founders Mary Antony and Kelsey Gootnick launched the AI-powered financial reporting platform in 2023 after meeting at Flexport seven years earlier. The startup automates manual tasks in financial statement preparation such as math verification and formatting. Antony said ensuring dollar signs and commas are uniform can save accountants up to 20 percent of their time. The company has not yet fully automated generation of income statements and balance sheets. InScope grew its customer base by five times over the last 12 months with clients including CohnReznick. Norwest partner Sean Jacobsohn said he invested after multiple clients reported that the product saves time. He added that the complex space requires founders with direct buyer experience.
Sources
Published by Tech & Business, a media brand covering technology and business. This story was sourced from TechCrunch and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.